Plus Therapeutics Presents New Health Economics Study Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Using CNSide Cerebrospinal Fluid Assay

PLUS THERAPEUTICS INC +23.66% Pre

PLUS THERAPEUTICS INC

PSTV

3.92

4.09

+23.66%

+4.34% Pre
Plus Therapeutics Presents New Health Economics Study Evaluating Economic Impact Of Earlier Detection And Therapeutic Management Of LM Using CNSide Cerebrospinal Fluid Assay